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Imiquimod Inhibits Melanoma Development by
Promoting pDC Cytotoxic Functions and Impeding
Tumor Vascularization
Caroline Aspord1,2,3, Laetitia Tramcourt1,2,3, Claire Leloup1,2,3, Jean-Paul Molens1,2,3,
Marie-Therese Leccia2,3,4, Julie Charles2,3,4,5 and Joel Plumas1,2,3,5
Imiquimod (IMQ) is a synthetic Toll-like receptor (TLR7/8) ligand that can trigger antiviral and antitumor activities.
Despite evidence of potent therapeutic effects, the clinical use of IMQ in melanoma is impeded by incomplete
understanding of its mechanisms of action. Mice and humans differ in many aspects of immunity, including TLR7
expression patterns, thus impeding the use of mouse models in translating discoveries into clinical applications.
In this article, we investigated the mechanisms behind IMQ effects in vivo in a human context of melanoma and
immunity using an innovative melanoma-bearing humanized mouse model. In this model, IMQ strongly
inhibited melanoma tumor development through prompt mobilization of plasmacytoid dendritic cells and by
triggering their cytotoxic functions, and through upregulation of expression of type 1 IFN response genes. IMQ
also drastically impeded tumor vascularization by inducing the downregulation of angiogenic factors vascular
endothelial growth factor, angiogenin, IL-8, and fibroblast growth factor. Our results revealed the short- and
long-term multifactorial effects of IMQ converging toward inhibition of melanoma development. By providing a
better understanding of the mechanisms of action of IMQ in melanoma, our study opens the way for its further
clinical use in the treatment of metastatic melanoma.
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INTRODUCTION
Imiquimod (IMQ) is a small molecule of the imidazoquinoline
family. It displays potent antiviral and antitumor activities
through broad direct and indirect effects in the skin and
immune system (Smits et al., 2008). A cream formulation
of 5% IMQ (ALDARA(TM)) has received Food and Drug
Administration approval for topical treatment of basal cell
carcinoma, actinic keratoses, and virus-induced skin
neoplasms (Stanley, 2002; Gaspari, 2007), and its use has
led to high cure rates (Geisse et al., 2004). A few case studies
reported the promising potential of IMQ in treating melanoma
lesions (Steinmann et al., 2000; Bong et al., 2002). However,
because of incomplete understanding of the mechanisms of
action and ongoing investigations into its antitumor effects, it
is not currently used to treat metastatic melanoma.
IMQ is a synthetic Toll-like receptor (TLR) agonist modulat-
ing innate immune responses through TLR7/8 triggering. It has
also been shown to have a proapoptotic activity, directly
inducing tumor cell apoptosis by triggering the caspase
pathway (Schon et al., 2004). Topical application of IMQ in
mice and humans induces a strong inflammatory response,
characterized by skin inflammation, infiltration, and activation
of immune cells, subsequently leading to T-cell activation and
antitumor adaptive immune responses (Hemmi et al., 2002;
Stanley, 2002). In humans, plasmacytoid dendritic cells
(pDCs) are the predominant cell type responding to TLR7-L
stimulation (Gibson et al., 2002). These cells have the unique
ability to sense single-stranded RNA and unmethylated DNA
motifs through expression of TLRs TLR7 and TLR9 (Cao and
Liu, 2007; Lande and Gilliet, 2010). Following TLR triggering,
pDCs produce large amounts of type 1 IFN and
proinflammatory cytokines, which modulate the innate and
adaptive immune responses. Interestingly, in melanoma, pDCs
are recruited to the tumor site and sentinel lymph nodes
(Salio et al., 2003; Vermi et al., 2003; Charles et al., 2010) but
they remain in a nonfunctional immature state. However,
activation by TLR-L primes pDCs for potent functional
responses in vitro (Salio et al., 2003; Rothenfusser et al.,
2004) and in vivo (Liu et al., 2008). Thus, CpG (TLR9-L) can
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promote tumor regression in mice (Furumoto et al., 2004) and
can improve melanoma patients’ response to vaccination
(Speiser et al., 2005) through pDC recruitment and
activation (Pashenkov et al., 2006; Molenkamp et al., 2007).
It has also been shown that topical application of IMQ (TLR7-
L) leads to potent antitumor effects involving pDCs in mice
(Palamara et al., 2004). Upon activation, pDCs may also
display direct cytotoxic activity toward tumor cells through
TRAIL expression, granzyme B, and lysozyme secretion
(Chaperot et al., 2006; Stary et al., 2007; Matsui et al., 2009;
Jahrsdorfer et al., 2010). Therefore, mobilization of pDCs
through TLR agonists could help control melanoma tumors.
Until now, IMQ has been mostly studied in mouse models
of melanoma. This has led to key advances, but the relevance
of these findings in humans has yet to be assessed. This is
essential as the immune systems in mice and humans are
different in many aspects (Mestas and Hughes, 2004). Thus,
results from animal research do not necessarily reflect human
outcomes (Seok et al., 2013). Specifically, mice and humans
differ in their TLR expression pattern, especially for TLR7
(Iwasaki and Medzhitov, 2004). In humans, within dendritic
cells (DCs), TLR7 is restricted to pDCs, whereas it is expressed
by several DC subsets in mice (pDCs, CD4þ DCs, and
dominant-negative DCs). Therefore, topical application of
IMQ in mice directly activates dermal DC and Langerhans
cells, and leads to maturation and migration of cutaneous DCs,
whereas in humans it mostly drives pDC mobilization and
activation. To date, in vivo IMQ studies are limited to murine
models of melanoma, and their results cannot be directly
translated into clinical applications. Studies in melanoma
patients are restricted to case reports or short-term trials. This
prevents a detailed dynamic analysis of IMQ effects. A possible
tool to circumvent these restrictions is the use of humanized
mouse models, based on immunodeficient mice reconstituted
with a functional human immune system by injection of
human hematopoietic CD34þ stem cells. These animals can
then be further xenotransplanted with human tumors (Aspord
et al., 2007a,b). Humanized mice have proved to be powerful
tools in elucidating the underlying mechanisms of human
diseases and testing novel therapies, and have allowed many
advances in translational biomedical research, especially in the
field of cancer immunotherapy (Shultz et al., 2012).
Many aspects of the mechanisms of IMQ resulting in tumor
regression in a human context of melanoma and immunity are
still unknown. Moreover, available studies mostly focused on
pDCs; yet, other potential effects of IMQ in the context of
melanoma have not been investigated. In this article, we
investigated the effects of IMQ on melanoma in vivo using a
melanoma-bearing humanized mouse model. Our results
demonstrate that IMQ inhibited melanoma tumor development
by promptly mobilizing pDCs, triggering pDC cytotoxic func-
tions, and drastically impeding tumor vascularization. Thus, IMQ
triggered a host of actions that converge to inhibit melanoma
development. These results contribute to a better understanding
of the mechanisms of action of IMQ in the context of human
melanoma, underlining its strong therapeutic potential.
RESULTS
IMQ triggers potent immune-dependent inhibition of melanoma
tumor growth in a patient and in tumor-bearing humanized mice
IMQ has rarely been used over a long period to treat
metastatic melanoma lesions. To assess whether IMQ could
impede long-term tumor development in melanoma patients,
we treated a 50-year-old patient with 41 in-transit metastases
with IMQ 5% cream 5 days a week for 6 months. After an
initial inflammatory episode, all lesions disappeared within 6
months of initiating the treatment (Figure 1). To explore the
mechanisms underlying IMQ effects in vivo in the context of
human melanoma tumor and the human immune system, we
developed an innovative humanized mouse model in which
immunodeficient NOD-SCID (severe combined immunodefi-
cient) b2m
 / or NOD-SCID IL2RgC
 / mice were first
xenotransplanted with human CD34þ hematopoietic pro-
genitor cells (HPCs) before injecting them with human
melanoma cells (OncoHumice) (Figure 2a and b). These
OncoHumice harbored both a human tumor and a human
Start of treatment
Imiquimod application (5x/week)
+ 1 Month + 6 Months
Figure 1. Imiquimod effectively treats cutaneous metastasis in a melanoma patient. A 50-year-old patient with 41 in-transit melanoma metastases was treated
with imiquimod 5 days a week (starting in March 2009). After an initial inflammatory episode (April 2009), the lesions had totally disappeared by 6 months
(September 2009).
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immune system, revealed by the presence of human hemato-
poietic CD45þ cells including monocytes, B cells, myeloid
dendritic cells, and pDCs in NOD-SCID b2m
 / mice 4
weeks post engraftment (Supplementary Figure S1a online)
together with NK and T cells in NOD-SCID IL2RgC
 / mice
starting 8 weeks post engraftment (Supplementary Figure S1b
online). To investigate the overall antitumor effect of IMQ, we
treated OncoHumice daily with a topical application of
ALDARA(TM) 5% IMQ or control cream to the skin covering
the subcutaneous tumor. Melanoma tumor growth was sig-
nificantly reduced in animals treated with IMQ (Figure 2c and
d, Supplementary Figure S2a online). To determine whether
the immune system was involved in this antitumor effect, the
treatment was also applied in OncoMice, which are immu-
nodeficient NOD-SCID b2m
 / mice engrafted only with
human melanoma cells and therefore deprived of human
immune cells. In these mice, no difference in the evolution of
tumor growth was observed between animals treated with
IMQ or the controls (Figure 2e and f). Thus, IMQ triggered
potent immune-dependent inhibition of melanoma tumor
growth in OncoHumice.
IMQ promptly mobilizes and activates pDCs within tumors in
melanoma-bearing humanized mice
We next assessed how IMQ affected mobilization of human
pDCs in melanoma-bearing humanized mice. pDCs are the
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Figure 2. Imiquimod triggers potent immune-dependent inhibition of melanoma tumor growth in tumor-bearing humanized mice. OncoHumice were
constructed by intravenous xenotransplantion of human CD34þ hematopoietic progenitor cells (HPCs) into sublethally irradiated NOD-SCID (severe combined
immunodeficient) b2m
 / mice, followed by subcutaneous implantation of melanoma tumor cells. OncoHumice thus have both a human immune system,
including plasmacytoid dendritic cells (pDCs), and human tumors. OncoMice, in contrast, received only the melanoma cells. All mice received daily topical
applications of ALDARA(TM) 5% cream or control cream until sacrifice, and tumor growth was monitored. (a) OncoHumouse model. (b) Human CD45þ
hematopoietic cell percentages measured in different organs on day 3 of treatment (n¼ 27 OncoHumice per group). (c) Representative tumor growth curves for
OncoHumice (n¼ 5 OncoHumice per group). (d) Tumor size on days 23–26 in OncoHumice (n¼ 19 OncoHumice per group). (e) Representative tumor growth
curves for OncoMice (4–5 OncoMice per group). (f) Tumor size on day 14 in OncoMice (n¼16–18 OncoMice per group). P-values: Mann–Whitney test. BM,
bone marrow; DLN, draining lymph nodes.
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main human cell type expressing TLR7 and are therefore likely
to respond to IMQ. Strikingly, following IMQ application,
prompt mobilization of pDCs to the melanoma tumor site was
observed (Figure 3a and b, Supplementary Figure S2b online);
no such mobilization was seen with the control treatment.
This recruitment was associated with a concomitant depletion
of pDCs from the bone marrow (Figure 3c, Supplementary
Figure S2c and S2d online). IMQ did not modulate other
human cell populations at the tumor site (Supplementary
Figure S3 online). Notably, a signature of pDC activation
was detected in the plasma and tumor microenvironment
of OncoHumice treated with IMQ, as human IFN-a and
IP10 were observed in the plasma and tumor supernatants
of OncoHumice treated with IMQ (Figure 3d and e).
Furthermore, IMQ rapidly triggered the upregulation of expre-
ssion of human type 1 IFN genes and type 1 IFN response
genes within the tumor microenvironment (Figure 4). Thus,
IMQ promptly mobilized and activated pDCs within the
melanoma tumor site.
IMQ potently triggers the cytotoxic functions of pDCs
To further investigate how IMQ modulates pDCs, we analyzed
the phenotypic and functional changes triggered by IMQ on
purified human pDCs in vitro, focusing particularly on their
cytotoxic potential. Within 24 hours, IMQ elicited a dramatic
upregulation of the death-inducing ligand TRAIL on the
surface of pDCs (Figure 5a) combined with potent granzyme
B degranulation (Figure 5b) as attested by the loss of
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Figure 3. Imiquimod promptly mobilizes plasmacytoid dendritic cells (pDCs) within the tumor site in vivo in melanoma-bearing humanized mice. NOD-SCID
(severe combined immunodeficient) b2m
 / immunodeficient mice received human CD34þ hematopoietic progenitor cells (HPCs) followed by human
melanoma tumor cells. ALDARA(TM) 5% cream or control cream was applied to the skin daily from the day of tumor implantation. (a–c) Human pDCs were
determined within the total human CD45þ hematopoietic cells based on HLA-DR and BDCA2 expression. (a) Representative dotplots of pDCs at the tumor
site (gated on CD45þ cells). (b) Percentage of pDCs at the tumor site at different times (n¼4–9 OncoHumice/group). P-values: two-way analysis of variance test.
(c) Percentage of pDCs within CD45þ cells in organs within 3 days of treatment (n¼ 14 OncoHumice per group) (data from d1, d2, and d3 are pooled).
(d) Plasma IFN-a and IP10 levels 3 days after initiating imiquimod treatment (n¼ 14 OncoHumice per group). (e) IFN-a and IP10 levels in tumor supernatants
3 days after the start of imiquimod treatment (n¼ 14 OncoHumice per group). P-values: Mann–Whitney test.
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intracellular granzyme B stocks in pDCs. Strikingly, pDCs
treated with IMQ acquired the ability to kill TRAIL-sensitive
melanoma tumor cells (Figure 5c, Supplementary Figure S4
online). Given the strong effect of IMQ on pDCs observed
in vitro, we next investigated the in vivo consequences on
pDC functions following IMQ administration in melanoma-
bearing humanized mice. TRAIL expression was potently
upregulated by pDCs within the tumor microenvironment
(Figure 5d) and granzyme B degranulation occurred (Figure 5e).
IMQ was also found to trigger monocyte chemotactic protein1
and IL-21 production at the tumor site (Supplementary Figure
S5a online) and elevated plasma levels of fractalkine, I-transit
amplifying cell, and monokine induced by gamma interferon
were measured in IMQ-treated OncoHumice (Supplementary
Figure S5b online). Thus, IMQ creates a cytokine and
chemokine network eliciting pDC and T-cell mobilization
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Figure 4. Imiquimod triggers the upregulation of type I IFN-inducible genes at the tumor site of melanoma-bearing humanized mice. NOD-SCID (severe
combined immunodeficient) IL2RgC
 / immunodeficient mice received human CD34þ hematopoietic progenitor cells followed 4 weeks later by human
melanoma tumor cells. ALDARA(TM) 5% cream or control cream was applied to the skin daily. The expression of type I IFN (IFN-a2, IFN-b1) as well as human
type I IFN-inducible genes (ISG15, G1P3, MX1, CXCL10) was analyzed at the tumor site by reverse transcription-real time PCR on day 1 (a, n¼ 6–8 OncoHumice
per group) and day 3 (b, n¼ 8 OncoHumice per group) after the start of the treatment. P-values: Mann–Whitney test.
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and function, and endowing them with potent cytotoxic
activity toward melanoma tumor cells.
IMQ drastically inhibits tumor vascularization in vivo in
melanoma-bearing humanized mice
Vascularization being important in supporting tumor growth,
we investigated the effects of IMQ administration on the levels
of proangiogenic factors. Levels of vascular endothelial growth
factor (VEGF), angiogenin, IL-8, and fibroblast growth factor
were significantly decreased within the melanoma microen-
vironment of OncoHumice treated with ALDARA(TM) com-
pared with levels in control animals (Figure 6a, upper panels).
This difference was not observed in OncoMice deprived of the
human immune system (Figure 6a, lower panels). We then
assessed whether these features could impact tumor vascular-
ization. Strikingly, the overall density of blood vessels within
tumors was significantly lower in IMQ-treated OncoHumice
than in animals receiving control treatment at day 16 and day
24 after the start of treatment (Figure 6b and c, left panels).
Moreover, by counting the number and measuring the area of
blood vessels, the structure of the vasculature within tumors
was also found to be significantly different with IMQ-treated
tumors displaying significantly more small (50–200mm2) and
fewer large (4500mm2) blood vessels compared with tumors
receiving the control treatment (Figure 6d, left panels). In
contrast, tumor vascularization was not affected in IMQ-
treated OncoMice (Figure 6b–d, right panels). Thus, IMQ
drastically remodeled the tumor vasculature and inhibited
vascularization in an immune-dependent manner.
DISCUSSION
In view of the clinical interest for TLR7 agonists in metastatic
melanoma, it is essential to determine the mechanism of
action of IMQ. Our study uses a highly relevant model of
humanized mice to confirm the key role of pDCs in translating
the effects of IMQ into potent tumor growth restriction. Our
results also revealed a previously unexpected role for IMQ
inhibiting tumor vascularization. These additional insights will
have a major impact on the use of IMQ as treatment against
metastatic melanoma.
Humanized mice were used in this study to elucidate the
effects of IMQ in the context of melanoma. Studies in humans
are hindered by restricted access to tissues and ethical
concerns, and do not allow to investigate mechanisms of
action or disease pathogenesis. Studies of IMQ effects in
humans are limited to case reports (Steinmann et al., 2000;
Bong et al., 2002; Zeitouni et al., 2005), being mostly
descriptive and not investigational. The few data available
regarding the effects of IMQ on immunity in melanoma
patients revealed an IFN signature in the serum of patients
(Dummer et al., 2008) suggesting an activation of pDCs and
an increase in T cells in the treated area (Narayan et al., 2012).
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Figure 5. Imiquimod triggers the cytotoxic functions of pDCs in vitro and in vivo in melanoma-bearing humanized mice. (a–c) pDCs purified from healthy
donor blood were treated with imiquimod. pDC features were assessed after 4, 24, and 48 hours. (a) TRAIL expression at 24 hours (n¼ 7). (b) Intracellular
granzyme B (grB) staining (n¼ 6–12). (c) Cytotoxicity of pDCs toward melanoma tumor cells measured by annexinV (annV) staining of COLO829 and A375 after
18-hour co-cultures with imiquimod (IMQ) (2.5mg ml1)-stimulated plasmacytoid dendritic cells (pDCs) (E:T ratios: 40:1 or 20:1) (n¼ 11). (d, e) NOD-SCID
(severe combined immunodeficient) b2m
 / immunodeficient mice received human CD34þ hematopoietic progenitor cells followed by subcutaneous
implantation of human melanoma tumor cells. ALDARA(TM) 5% cream or control cream was applied topically to the tumor daily. (d) TRAIL expression
on pDCs within the tumor microenvironment on day 3 of imiquimod treatment (n¼12–13). (e) Granzyme B (grB)þ pDCs in different organs on day 3 of
imiquimod treatment (n¼ 5). P-values: Wilcoxon’s matched pairs test.
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Figure 6. Imiquimod drastically inhibits tumor vascularization in vivo in melanoma-bearing humanized mice. NOD-SCID (severe combined immunodeficient)
b2m
 / immunodeficient mice were transplanted with human CD34þ hematopoietic progenitor cells (OncoHuMouse) or not transplanted (OncoMouse)
followed by subcutaneous injection of human melanoma tumor cells. Tumors were treated daily by topical application of ALDARA(TM) 5% cream or control
cream. (a) Vascular endothelial growth factor (VEGF), angiogenin, IL-8, and fibroblast growth factor (FGF) levels at the tumor site on days 3–30 of treatment
(n¼ 17–19 OncoHumice per group; n¼ 20 OncoMice per group). (b–d) Tumor vascularization on days 16 and 24 of treatment. Vascularization was visualized
after FITC-lectin injection and fluorescence microscopy analysis of tumor sections. (b) Representative tumor sections (bar¼200mm). (c) Surface occupied by blood
vessels (percentage of thresholded area) on days 16–24 (left panel: n¼ 35 sections from 8 OncoHumice per group; right panel: n¼58–81 sections from 8–10
OncoMice per group). (d) Size distribution for vessels 16–24 days after starting treatment (left panel: n¼35 sections from 8 OncoHumice per group; right panel:
n¼ 52 sections from 8–10 OncoMice per group). P-values: (a, c) Mann–Whitney test; (d) two-way analysis of variance (ANOVA).
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Strikingly, our results not only describe immune effects but
also reveal vascular effects. Human CD34þ HPCs, which
were used to reconstitute the immune system in these animals,
also contain endothelial progenitor cells, which are known to
contribute to tumor angiogenesis (Hristov et al., 2003; Ribatti,
2004). Thus, humanized mice represent a relevant model with
which to decipher interactions between immune and tumor
cells, to perform dynamic in vivo analysis, and to further
translate discoveries into clinical applications.
IMQ triggered prompt mobilization of pDCs to the tumor
site; this was not observed with the control treatment. Notably,
the early IFN-a and IP10 signature in the plasma and tumor
microenvironment of humanized mice treated with ALDAR-
A(TM) revealed a potent activation of the mobilized pDCs.
Interestingly, a short-term trial using the TLR7-L agonist 852A
in metastatic melanoma patients demonstrated similar increases
in serum levels of type I IFN and IP10 in most treated patients
(Dummer et al., 2008). Our results also showed elevated
levels of monocyte chemotactic protein1/CCL2 and IL-21 in
the tumor microenvironment following IMQ application but
not with control treatment. monocyte chemotactic protein1/
CCL2 may contribute to pDC recruitment (Drobits et al.,
2012), whereas IL-21 has been shown to be implicated in
triggering pDC degranulation (Karrich et al., 2013), increasing
the potential of cytotoxic effector T and NK cells (Park et al.,
2012; Turksma et al., 2013) and hampering Treg expansion
(Battaglia et al., 2013). Interestingly, IL-21 was found to be
clinically active in a phase II study in melanoma patients
(Petrella et al., 2012). Other chemokines were also elevated in
the plasma of IMQ-treated humanized mice, including
fractalkine/CX3CL1, I-transit amplifying cell/CXCL11, and
monokine induced by gamma interferon/CXCL9. In the
context of melanoma, these chemokines have been shown
to favor CD8 T-cell infiltration and to be potent lymphocyte
chemoattractants (Hensbergen et al., 2005; Nukiwa et al.,
2006; Harlin et al., 2009). Thus, IMQ triggers events that may
potentiate subsequent adaptive antitumor immune responses.
The pDCs recruited by IMQ may contribute to inhibiting
tumor development in many ways. They could directly kill
tumor cells, as IMQ potently triggered pDC cytotoxic func-
tions through TRAIL upregulation and granzyme B degranula-
tion both in vitro and in vivo in the humanized mouse model.
This mechanism has been described in vitro (Kalb et al., 2012)
and is supported by data from a mouse model of melanoma
showing that IMQ drives pDC recruitment and their
subsequent conversion into tumor-killing effector cells
through TRAIL and granzyme B secretion (Drobits et al.,
2012). Tumor cell killing may generate apoptotic bodies and
release antigens that can then be processed by DCs for cross-
presentation to T cells to elicit specific antitumor responses. In
response to IMQ, pDCs secrete IFN-a, which can also directly
trigger tumor cell apoptosis through a caspase-dependent
mechanism (Thyrell et al., 2002). This leads to upregulation
of cytotoxic molecules and their corresponding ligands on
effectors and target tumor cells (Stary et al., 2007), thereby
potentiating the destruction of tumor cells. IP10 produced by
pDCs may promote a Th1-prone immunity, which will tend to
elicit efficient antitumor responses. Thus, IMQ triggers a
number of pathways through pDCs, which converge to
inhibit tumor development.
Melanoma tumor cells secrete many potent angiogenic
factors such as VEGF, fibroblast growth factor, angiogenin,
and IL-8, which drive angiogenesis, critical for tumor growth
and invasiveness, and also display autocrine and paracrine
growth factor properties (Graeven et al., 2001). Tumor cell
elimination may thus directly reduce the level of tumor-
derived factors, especially proangiogenic factors. This
hypothesis is supported by the decreased levels of VEGF,
angiogenin, IL-8, and fibroblast growth factor observed in the
tumor microenvironment in this study. The large amounts of
IFN-a and IP10 produced by pDCs in response to IMQ
stimulation are described to be antiangiogenic (Sidky and
Borden, 1987; Sgadari et al., 1996), and can downregulate
VEGF and fibroblast growth factor production (Riedel et al.,
2000). Strikingly, the findings presented here are confirmed in
a case report in melanoma patients where IMQ treatment of a
skin metastasis caused changes to the expression levels of
genes involved in metastasis and angiogenesis (Hesling et al.,
2004). Indeed, the analysis of biopsies of skin lesions before
and after topical IMQ treatment revealed that IMQ triggered
the upregulation of IFN-a and angiogenesis inhibitors while
downregulating genes involved in angiogenesis and metastatic
invasion. In melanoma, VEGF is considered to be the main
proangiogenic factor promoting tumor growth and
invasiveness (Graeven et al., 2001). VEGF has mitogenic
properties on endothelial cells, promotes vascular per-
meability, and triggers the release of matrix metallopro-
teinases by endothelial cells to facilitate invasion into the
surrounding tissue. Vascularization is critical for tumor growth
and invasiveness. By impeding it, IMQ blocks an essential step
of tumor development. Notably, high serum levels of the
angiogenic factors VEGF, angiogenin, and IL-8 are associated
with poor clinical outcome in metastatic melanoma patients,
correlating with tumor progression and reduced survival
(Ugurel et al., 2001). These factors are therefore predictive
markers of overall and progression-free survival.
pDCs are key regulators of immune responses (Colonna
et al., 2004; Lande and Gilliet, 2010). Depending on their
maturation state and on the microenvironment, pDCs can
induce immunity or tolerance. The extensive functional plasticity
of pDCs gives them the capacity to direct immunity toward
multiple profiles depending on the surrounding signals. In
melanoma, pDCs within the tumor microenvironment are in a
nonfunctional state and are associated with a poor clinical
outcome (Jensen et al., 2012). However, several studies
demonstrated that mobilization and activation of pDCs using
TLR7 and TLR9 agonists allowed potent functional antitumor
responses, eventually leading to tumor regression in animal
models. pDC reactivation seems to be essential for the
antitumor response induced by IMQ (Drobits et al., 2012).
Thus, IMQ could tip the balance in favor of immunity over
tolerance. Our results corroborate the hypothesis that
reactivation of pDCs in the context of melanoma using TLR
agonists is a way of impeding tumor development.
IMQ may contribute to antitumor responses by affecting
tumor cells, tumor-infiltrating immune cells, and the tumor
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microenvironment. This broad range of antitumor activities
make IMQ a good candidate for its further clinical use as
adjuvant combined with others therapies, particularly to
enhance immunotherapy (Smits et al., 2008). Its therapeutic
potential is currently being investigated in preclinical studies
in animals and in patients in whom topical IMQ is used in
combination with other strategies. IMQ improved response to
DC-based vaccination in mice by promoting tumor-specific
T-cell priming and trafficking (Prins et al., 2006) and drove
specific responses toward coadministered antigens in patients
(Adams et al., 2008). The combination of topical IMQ and
photodynamic therapy in patients induces regression of distant
metastases and triggers beneficial immune responses (Naylor
et al., 2006). IMQ together with intralesional IL-2 induced
systemic immunological effects, reversing the Th1/Th2
balance (Green et al., 2008).
Our study highlights the relevance of IMQ in a human
context of immune cells and melanoma tumor cells and
provides further insights into the antitumor effects of IMQ.
Thanks to our innovative model of melanoma-bearing huma-
nized mice, we were able to show that pDCs, promptly
mobilized by IMQ, may also contribute to triggering long-term
inhibition of angiogenesis. Humanized mice could be used
further to design IMQ dosing schedules, optimize timing of
administration, or test IMQ in combination with other immu-
notherapies in preclinical trials, thereby opening opportunities
for future changes in clinical practice. Manipulating the immune
system using IMQ may be a potent means to trigger several
pathways converging into inhibition of tumor development. The
potent antitumor effects of IMQ through pleiotropic pathways
make it very attractive for further clinical developments.
MATERIALS AND METHODS
Melanoma patient
A 50-year-old patient was diagnosed with a primary melanoma on
the arm in 2007 (Breslow 3.5 mm, ulcerated). The melanoma was
surgically removed, but 41 in-transit cutaneous melanoma metastases
developed in March 2009. IMQ 5% cream (ALDARA(TM)), marketed
in France by MEDA Laboratories, was applied to all lesions 5 days a
week for 6 months (3 packages of 12.5 mg per day for all lesions). A
spectacular disappearance of all metastases was observed in Septem-
ber 2009. IMQ application was then reduced to twice a week. The
patient received no other treatment before and during IMQ applica-
tion. The patient gave written informed consent for participation in
the study. The study was approved by the Ethics committee of
Grenoble University Hospital and performed with adherence to
Helsinki Guidelines.
Melanoma cell lines and human CD34þ HPCs isolation
Human melanoma lines COLO829 and A375 were purchased from
ATCC (LGC Standards, Molsheim, France) and cultured in RPMI 1640
Glutamax supplemented with 1% non-essential amino acids, 1 mM
sodium pyruvate (Sigma, Lyon, France), 100mg ml 1 gentamycin, and
10% fetal calf serum (all from Invitrogen, Saint Aubin, France, unless
indicated). Human CD34þ HPCs were purified from cord blood using
a CD34 HPCs isolation kit (Miltenyi, Paris, France) and stored frozen
until use. This procedure was approved by the French Blood Service’s
Institutional Review Board, and donors gave written informed consent.
In vitro modulation of pDC phenotype and function by IMQ
Blood samples were obtained from 38 healthy volunteers. This
procedure was approved by the French Blood Agency’s Institutional
Review Board and participants signed informed consent forms.
PBMCs were purified from blood by Ficoll-Hypaque density-gradient
centrifugation (Eurobio, Courtaboeuf, France) and pDCs were further
purified using the EasySep Human pDC enrichment kit (StemCell,
Grenoble, France) (purity497%). pDCs were stimulated for 4, 24, or
48 hours with the indicated doses of IMQ (R837). Flow cytometric
analysis (FACSCalibur, BD, Paris , France) was used to determine
levels of costimulatory and death-inducing molecules using anti-
CD40, -CD80, -CD86 (Beckman), -TRAIL, and -granzyme B (BD)
antibodies. A Cytometric Bead Array assay (BD) was used to quantify
IFN-a, IP10, IL-6, IL-8, and TNF-a cytokines in culture supernatants.
The sensitivity of COLO829 and A375 melanoma tumor cells to
TRAIL-mediated killing was assessed by incubating the tumor cells
with soluble TRAIL and labeling with 7 aminoactinomycin D after 4,
18, and 48 hours. Killer TRAIL (100 ngml 1) (Axxora, Villeurbanne,
France) was used as positive control of TRAIL-induced death. pDC
cytotoxicity toward melanoma tumor cells was measured in co-
cultures of IMQ-stimulated (2.5mg ml 1) pDCs with COLO829 and
A375 melanoma tumor cells at 20:1 to 1:1 ratios for 18 hours followed
by annexinV FITC and 7 aminoactinomycin D labeling of tumor cells.
Humanized mice
NOD-SCID b2m
 / (NOD.Cg-PrkdcSCIDb2m
Tm1Unc/J) and NOD-
SCID IL2RgC
 / (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ) immunodeficient
mice were purchased from Jackson ImmunoResearch Laboratories
(Bar Harbor, MI) and bred at the Plateforme de Haute Technologie
Animale (PHTA, La Tronche, France). Humanized mice were con-
structed by intravenous xenotransplantion of 1–2 105 human
CD34þ HPCs into sublethally irradiated 4-week-old immunodeficient
mice (100–120 cGy). The human immune system was reconstituted
within 4 weeks in both strains, except for human NK and T cells, which
developed from 8 weeks post transplantation only in NOD-SCID
IL2RgC
 / recipient mice. Then, 10 106 human melanoma tumor
cells were implanted subcutaneously into the flank of the humanized
mice (OncoHumice). In some experiments, NOD-SCID b2m
 /
immunodeficient mice were only implanted with 10 106 human
melanoma tumor cells without prior immune reconstitution (Onco-
Mice). All in vivo studies were carried out in strict accordance with
European Union guidelines (86/609/CEE) and French National Charter
guidelines; protocols were approved by the local Ethics Committee
for Animal Experimentation, Grenoble (ComEth).
ALDARA(TM) treatment of melanoma-bearing humanized mice
Tumors received daily topical treatment with ALDARA(TM) 5%
cream (3 mg per mouse) (Meda Pharma, Paris, France) or control
cream without IMQ from the day of implantation until sacrifice.
Tumor growth was measured every 2–3 days using a caliper, and the
tumor volume was calculated using the ellipsoid formula: (length
width)2/2.
Analysis of pDC phenotype and function by flow cytometry
At different time points after the start of ALDARA(TM) treatment,
tumors, draining lymph nodes, control lymph nodes, spleen, and
bone marrow were harvested. Organs were digested with 2 mg ml 1
collagenase D (Roche, Boulogne, France) and the resultant cell
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suspensions were filtered, washed, resuspended in phosphate-buffered
saline supplemented with 2% fetal calf serum, and counted before
staining with anti-human antibodies. pDCs (CD45þ HLA-DRþ
BDCA2þ ) were identified using anti-CD45 FITC, anti-HLA-DR PerCP
(BD), and anti-BDCA2 APC antibodies (Miltenyi). Their basal activa-
tion level was determined using anti-CD40, -CD80, and -CD86 FITC/
PE antibodies and their isotype-matched controls (Beckman Coulter,
Paris, France). TRAIL expression was measured by surface staining
using anti-CD253 Abs (BD), and intracellular granzyme B was
quantified using anti-grB Abs (BD). Suspensions were then submitted
to flow cytometric analysis on a FACSCalibur using Cell Quest
software (BD) for acquisition and anlaysis.
RTqPCR quantification of gene expression
Reverse transcription-real time PCR assays with Universal Probe
Library probes have been performed in this study according to the
recommendations of the supplier (Roche). The primers and Universal
Probe Library probes used are listed in Supplementary Table S1
online. Tumors were taken from mice and put immediately in
RNAlater and kept at  20 1C. Total RNA was extracted following
disruption of the tumor with tissue ruptor apparatus (Qiagen,
Courtaboeuf, France) and submitted to an extraction procedure using
the Qiagen kit according to the recommendations of the supplier.
Following treatment with a Turbo DNAse (Ambion, Saint Aubin,
France) to remove genomic DNA, cDNA was obtained from RNA
using the expand transcriptase reverse enzyme from Roche and
submitted to qPCR.
Cytometric bead array for plasma and tumor factor
quantification
Blood samples were collected from humanized mice in heparinized
tubes and plasma was separated. Small tumor fragments (about
10 mm3) were incubated in 100ml complete RPMI 1640 Glutamax
supplemented with 10% fetal calf serum. Culture medium was
recovered 24 hours later as tumor supernatants. The following human
cytokines, chemokines, and angiogenic factors were quantified in
plasma and tumor supernatants by Cytometric Bead Array assay (BD):
IFN-a, IP10, IL-8, IL-21, fractalkine, I-transit amplifying cell, mono-
kine induced by gamma interferon, monocyte chemotactic protein1,
VEGF, and angiogenin.
Measuring tumor vascularization in vivo
Tumor vasculature was analyzed after intravenous injection of FITC-
labeled Lycopersicon esculentum lectin (100mg per 100ml) (Sigma)
followed 10 minutes later by perfusion of 0.5% glutaraldehyde 1%
paraformaldehyde in phosphate-buffered saline. Tumors were imme-
diately frozen in tissue-tek OCT and stored at  80 1C. Cryosections
(5mm) were prepared using a cryostat and mounted with diamidino-
phenylindol-containing mounting medium (Invitrogen). Sections were
analyzed by fluorescence microscopy using a motorized Axio Imager
M2 apparatus (Zeiss, Marly le Roi, France) with plan-Apochromat
 20/0.75 NA and Axiovision software equipped with the MosaiX
module. The surface occupied by blood vessels was quantified
(percentage of thresholded area) and the vessel number and area
were determined after thresholding and segmentation using Meta-
morph software (Molecular Devices, St Gregoire, France). To correct
for heterogeneity of vasculature, sections were imaged at 3–4
different depths in each tumor sample, and whole tumor sections
were analyzed. For each section, the number and area of each vessel
were determined, and the relative proportion of vessels ranked by size
was then calculated.
Statistical analysis
All statistical analyses were performed using Prism software (Graph-
Pad software, La Jolla, CA) by using the Mann–Whitney nonpara-
metric U-test, the unpaired t-test, and one- and two-way analysis of
variance.
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